Hypersensitivity Clinical Trial
Official title:
Investigating the Efficacy of Artificial Tear Supplements and Cold Compresses for the Treatment of Seasonal Allergic Conjunctivitis
Seasonal allergic conjunctivitis (SAC) is an irritating eye condition that affects many people, caused by hypersensitivity to normally harmless substances such as pollen, and often accompanies seasonal hay fever. Treatments that can be used before initiating medical therapy include artificial tear supplements (ATS) and cold compresses (CC). However, there is no evidence in the scientific literature that demonstrates their efficacy compared to no treatment or their combined effect with anti-allergic medication. Therefore the investigators aim to examine the efficacy of ATS and CC alone, in comparison to anti-allergic medication, and CC in combination with anti-allergic medication. In addition, the investigators also aim to determine the time course of ocular allergic reactions. At the end of the study the investigators will be able to see whether or not ATS and CC are effective in treating SAC.
There will be a total of 6 study visits, each lasting approximately 1 hour and separated by
at least 2 days. At the beginning of each visit, a set of measurements will be taken by an
experienced optometrist. These are:
- What symptoms you are feeling and how severe they are - you will be asked to complete a
short questionnaire about how your eyes currently feel.
- The redness and temperature of your eyes - the front surface of both eyes will be
photographed using digital cameras.
After these measurements we will ask you to stand inside a specially designed room where the
environment can be controlled by a computer. The pollen that you were found to be allergic to
will then be introduced into the atmosphere of the room, so that the signs and symptoms of
SAC can be induced - this is intentional, but normally resolves within a few hours with no
treatment. At each visit, you will experience a different duration (no longer than 10
minutes) and either no treatment, artificial tear supplement (ATS; preservative free ocular
lubricant), cold compress (CC; cooled gel eye mask) or anti-allergic medication (epinastine
hydrochloride 500μg/mL). The measurements will then be repeated even 5 minutes for an hour.
After the final set of measurements, the front surface of your eyes will be assessed using a
temporary dye to highlight using a blue light any changes. Fluorescein dye does not sting,
lasts only a few minutes and has no effect on vision or driving. However it may cause a self
limiting mild allergic reaction where the eyes become red, irritated and sore but this is
highly unlikely as there are no known reported cases. In the unlikely event this does happen
the experienced optometrist is immediately available to manage the condition.
The anti-allergic drug epinastine hydrochloride (Elestat, Allergan) is a prescription only
medicine indicated for the treatment of allergic conjunctivitis. As with all medications,
there are potential side effects - although uncommon (1 in 10 to 1 in 100 people), there may
be a slight burning sensation on application but this temporary and subsides quickly. The
epinastine formulation also contains preservatives called benzalkonium chloride and disodium
edetate. As with fluorescein sodium, these may cause a self limiting mild allergic reaction.
In the unlikely event this does happen the experienced optometrist is immediately available
to manage the condition.
Study Length and Reimbursement Each of the 6 measurement visits is separated by 7 days
therefore the total study length for each participant is 6 weeks.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04531540 -
Study to Determine Skin Irritation and/or Sensitization Potential of an Antifungal Cream Containing Trolamine (Repeated Insult Patch Test)
|
Phase 3 | |
Completed |
NCT00988065 -
Sugammadex Hypersensitivity Study (Study P06042)
|
Phase 1 | |
Completed |
NCT03563066 -
Effect of Benralizumab in Atopic Dermatitis
|
Phase 2 | |
Completed |
NCT02588326 -
Sensitivity of Pharmacokinetics to Differences in Particle Size Distribution of Suspension-based Nasal Sprays
|
Phase 1 | |
Completed |
NCT02916888 -
A Study Comparing the Quality of Life of Patients in the Treatment of Eczema by Pediatric Generalists and Specialists
|
N/A | |
Completed |
NCT02360072 -
Airway Inflammation and Bronchial Hyperresponsiveness in Rhinitic Children With or Without Asthma
|
||
Completed |
NCT02352168 -
Airway Inflammation in Children With Allergic Rhinitis and Intervention
|
N/A | |
Completed |
NCT01904604 -
Peanut Epicutaneous Phase II Immunotherapy Clinical Trial
|
Phase 2 | |
Completed |
NCT01494649 -
Pilot Study to Investigate the Efficacy of a Toothpaste in Providing Relief From Dentinal Hypersensitivity
|
N/A | |
Enrolling by invitation |
NCT05039229 -
Measures for Bioaerosol Reduction in the Salmon Industry
|
N/A | |
Enrolling by invitation |
NCT05675241 -
Characterizing the Inflammation Around Dental Implants
|
||
Completed |
NCT04006106 -
Defining ENDOtypes in Perioperative Hypersensitivity by Extensive Cellular and Molecular PHENotyping (ENDOPHEN)
|
||
Completed |
NCT04605471 -
A Study to Learn More About the Safety of Ultravist in Children and in the Elderly
|
||
Completed |
NCT03720470 -
Study Evaluating Efficacy and Safety of PF-04965842 and Dupilumab in Adult Subjects With Moderate to Severe Atopic Dermatitis on Background Topical Therapy
|
Phase 3 | |
Terminated |
NCT05247567 -
Quaternary Ammonium and Immunization in Hairdressers
|
N/A | |
Completed |
NCT05119751 -
Vestibular Versus Sublingual Route of AIT Tablets
|
Phase 4 | |
Recruiting |
NCT06065137 -
Standardised Drug Provocation Testing in Perioperative Hypersensitivity
|
N/A | |
Active, not recruiting |
NCT05960266 -
Immunological Analysis of Lymph Node Tissue After Intralymphatic Immunotherapy: A Prospective Case Control Study
|
Early Phase 1 | |
Not yet recruiting |
NCT04485299 -
Clinical Assessment of Bifluorid 10 vs Varnish Fluoride on The Exposed Hypersensitive Cervical Dentin in Adult Patient
|
Phase 2/Phase 3 | |
Completed |
NCT02686827 -
DBPC-Dose-finding-trial of Vitamin D3 for SCIT in Birch Pollen Allergic Patients.
|
Phase 2 |